Zelira Therapeutics (ASX:ZLD) Institutional Ownership: 0.03% (As of Jul. 11, 2026)


What is Zelira Therapeutics Institutional Ownership?

Zelira Therapeutics ASX:ZLD Institutional Ownership is 0.03% as of Jul. 11, 2026. The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zelira Therapeutics's institutional ownership is 0.03%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zelira Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zelira Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.

Zelira Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Institutional Ownership Chart

Zelira Therapeutics Historical Data

The historical data trend for Zelira Therapeutics can be seen below:

2016-04-30 2016-05-31 2016-06-30 2016-07-31 2016-08-31 2016-09-30 2018-03-31 2018-04-30 2018-05-31 2018-06-30
Institutional Ownership 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.06 0.06 0.03

Zelira Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 0.03% mean?
Zelira Therapeutics (ASX:ZLD) has a Institutional Ownership of 0.03% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Institutional Ownership too high?
Zelira Therapeutics' current Institutional Ownership is 0.03%.
How does Zelira Therapeutics' Institutional Ownership compare to MTNB and SXTP?
Zelira Therapeutics' Institutional Ownership of 0.03% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Institutional Ownership is 0.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Zelira Therapeutics (ASX:ZLD) has a current Institutional Ownership of 0.03%. The stock's GF Value™ is A$0.12, compared to a current price of A$0.50 — trading 316.7% above its estimated fair value. The current Institutional Ownership is 0.03%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Zelira Therapeutics (ASX:ZLD), the current Institutional Ownership is 0.03% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zelira Therapeutics Business Description

Other Exchanges ZLDAF:USA
Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.